Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 5Peripheral Nervous System Diseases 4Breast Neoplasms 4Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Head and Neck Neoplasms 3Stomatitis 2Stomach Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Mucositis 2Malnutrition 2Colorectal Neoplasms 2Wilms Tumor 1Sarcopenia 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Pain 1Oral Complications 1Neurotoxicity Syndromes 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Plasma Cell 1Multiple Endocrine Neoplasia Type 1 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Extranodal NK-T-Cell 1Lymphangioleiomyomatosis 1Lung Neoplasms 1

Interventions

Cyclophosphamide 26fludarabine 16Etoposide 15Melphalan 13romidepsin 12Gemcitabine 11Whole-Body Irradiation 10Vincristine 10Peripheral Blood Stem Cell Transplantation 10Doxorubicin 10fludarabine phosphate 9Rituximab 9Lenalidomide 9Cytarabine 9Busulfan 9pembrolizumab 8Prednisone 8Mycophenolic Acid 8Granulocyte Colony-Stimulating Factor 8Bortezomib 8Filgrastim 7Carmustine 7Brentuximab Vedotin 7Biopsy 7duvelisib 6Tacrolimus 6Specimen Handling 6Dexamethasone 6Bendamustine Hydrochloride 6ruxolitinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, T-Cell × Glutamine × Clear all
NCT02961816 2017-04-21

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡